Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and invigorating, because what has become a predictable routine of Zoom and Skype calls has, of course, now returned. This calls for our ritual coping mechanism — a delicious cup or three of stimulation. We are reaching, once again, for maple bourbon. Feel free to join us. Remember: No prescription is required. So you can avoid tallying rebates. Meanwhile, here are some tidbits to get you going. Have a grand day, and stay safe….

The U.S. is tying payments for Covid-19 vaccines to timing milestones for production and approval, Reuters reports. In a $1.5 billion deal with Moderna (MRNA), federal agencies negotiated a sliding scale of payments in which the company receives the funds in full if its vaccine receives regulatory clearance by Jan. 31, 2021, $1.2 billion if it falls short of that timing. Payments to other drug makers are also conditioned on launching clinical trials no later than early fall and building out manufacturing capabilities by the end of the year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!